This course is FREE with Unlimited CE!

Choose from two Unlimited CE subscription options and get access to 1000+ CE and professional development courses.

Get access starting at $49.95/yrLoading..

Goals and Learning Outcomes

Worldwide, about 71 million people are infected with the hepatitis C virus (HCV) (Saracco et al., 2022). In the U.S., it is estimated that 57,500 people are affected by acute HCV annually, and about 2.4 million people have chronic HCV (CDC, 2020a; 2021a). The World Health Organization (WHO) have endorsed a global strategy to eradicate HCV by 2030 (Saracco et al., 2022). Over the past several years, new classes of medications have been developed that are both highly effective and tolerable, allowing substantially more patients to achieve a cure for this disease. Healthcare providers (HCPs) should have knowledge of treatment modalities for patients who have HCV.

 

The goal of this course is to provide nursing professionals, pharmaceutical professionals, and physicians in acute care with guidance on the disease course and management of patients with HCV, who are treatment-naïve without cirrhosis or who have compensated cirrhosis.


After taking this course, you should be able to:

  • Discuss the epidemiology and pathophysiology of the hepatitis C virus, including the importance of screening, diagnosis, and fibrosis staging.
  • Determine the best treatment modality for patients who are treatment-naïve without cirrhosis or who have compensated cirrhosis, including monitoring, cost considerations, and barriers to treatment.
  • Prioritize ongoing patient care based on patient needs, such as complications from cirrhosis and nutritional needs.

Course Termination Date: Not yet determined

Content Expiration Date: 12/31/25

Course Originally Released On: 12/01/22

Course Authors

4.3 Average

Course Reviews

6981 reviews

Accreditation Information

Nurse.com Accreditation

In support of improving patient care, Relias LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Provider approved by the California Board of Registered Nursing, CEP#13791

Disclaimer: Not all courses will provide California Board of Registered Nursing approval. Per California Assembly Bill No. 241, continuing education courses related to direct patient care shall address at least one or a combination of the following:(1) Examples of how implicit bias affects perceptions and treatment decisions of licensees, leading to disparities in health outcomes; or (2) Strategies to address how unintended biases in decision-making may contribute to health care disparities by shaping behavior and producing differences in medical treatment along lines of race, ethnicity, gender identity, sexual orientation, age, socioeconomic status, or other characteristics.

 

CEBroker

Relias LLC reports to CEBroker for the following boards (Provider # 50-1489): Arkansas State Board Of Nursing, District Of Columbia Board Of Nursing, Florida Board Of Nursing, Georgia Board Of Nursing, Kansas State Board of Nursing, Kentucky Board of Nursing, Michigan Board of Nursing, Mississippi Board of Nursing, New Hampshire Board of Nursing, New Mexico Board Of Nursing, North Dakota Board of Nursing, South Carolina Board Of Nursing and West Virginia Board Of Registered Nurses

 

Please check the licenses/certifications section under my account (after logging in) to make sure you have entered a valid license number. This information is required for correct reporting of your course completions to CE Broker.

 

Disclosures

None of the planners/faculty, unless otherwise noted, for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.